文献速递前列腺癌

基线及纵向血浆小窝蛋白-1水平作为早期前列腺癌主动监测生物标志物

Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer.
PubMed 文献 · BJU Int · 2017-08-16

本研究在单中心主动监测队列中分析542例早期前列腺癌患者的存档血浆样本,评估小窝蛋白-1(Cav-1)对疾病重新分级的预测作用。中位随访3.1年后163例(30.1%)发生重新分级,基线Cav-1在多因素分析中为独立预测因子(OR 1.91,95%CI 1.28-2.84;P=0.001)。

要点

  • 基线血浆Cav-1水平是早期前列腺癌主动监测中疾病重新分级的独立预测因子。
  • 中位随访3.1年,542例中163例(30.1%)发生疾病重新分级。
  • 多因素校正年龄、肿瘤长度、风险分组和阳性针数后,Cav-1与重新分级风险仍显著相关。

核心结论

  • 基线血浆Cav-1水平是疾病重新分级的独立预测因子,可能有助于改进主动监测和干预方法。

研究设计与样本

  • 单中心主动监测研究,前瞻性收集早期前列腺癌患者存档血浆样本,825例入组患者中542例随访≥1年。
  • 采用酶联免疫吸附试验测定基线和纵向血浆Cav-1水平。
  • 疾病重新分级标准为肿瘤体积增大或Gleason分级升高。
  • 采用逻辑回归分析评估临床病理特征与重新分级风险的关联。

主要发现

  • 542例患者中480例(88.6%)为cT1c期,前列腺特异性抗原中位数4.1 ng/mL,531例(98.0%)癌症前列腺风险评估评分中位数为1,473例(87.3%)Gleason评分3+3。
  • 中位随访3.1年后,163例(30.1%)发生疾病重新分级。
  • 基线Cav-1均值2.2±8.5 ng/mL,中位数0.2 ng/mL(范围0-85.5 ng/mL)。
  • 单因素分析中基线Cav-1为疾病重新分级风险的显著预测因子(OR 1.82,95%CI 1.24-2.65;P=0.002)。
  • 多因素分析校正年龄、肿瘤长度、风险分组和阳性针数后,Cav-1相关重新分级风险仍显著(OR 1.91,95%CI 1.28-2.84;P=0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the role of caveolin-1 (Cav-1) as a predictor of disease reclassification (DR) in men with early prostate cancer undergoing active surveillance (AS). PATIENTS AND METHODS: We analysed archived plasma samples prospectively collected from patients with early prostate cancer in a single-institution AS study. Of 825 patients enrolled, 542 had ≥1 year of follow-up. Baseline and longitudinal plasma Cav-1 levels were measured using an enzyme-linked immunosorbent assay. Tumour volume or Gleason grade increases were criteria for DR. Logistic regression analyses were used to assess associations between clinicopathological characteristics and reclassification risk. RESULTS: In 542 patients, 480 (88.6%) had stage cT1c disease, 542 (100.0%) had a median prostate-specific antigen level of 4.1 ng/mL, and 531 (98.0%) had a median Cancer of the Prostate Risk Assessment score of 1. In all, 473 (87.3%) had a Gleason score of 3+3. After a median of 3.1 years of follow-up, disease was reclassified in 163 patients (30.1%). The mean baseline Cav-1 level was 2.2 ± 8.5 ng/mL and the median 0.2 ng/mL (range, 0-85.5 ng/mL). In univariate analysis, baseline Cav-1 was a significant predictor for risk of DR (odds ratio [OR] 1.82, 95% confidence interval [CI] 1.24-2.65; P = 0.002). In multivariate analysis, with adjustments for age, tumour length, group risk stratification and number of positive cores, reclassification risk associated with Cav-1 remained significant (OR 1.91, 95% CI 1.28-2.84; P = 0.001). CONCLUSION: Baseline plasma Cav-1 level was an independent predictor of disease classification. New methods for refining AS and intervention may result.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Basourakos SP, Davis JW, Chapin BF, et al. Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int. 2017. PMID: 28710901. doi:10.1111/bju.13963

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。